search
Disc Medicine
Trends
- 1
Disc Medicine is facing investor investigations following an FDA letter related to one of its drug programs. Law firms have announced probes into whether the biotech company misled shareholders about regulatory prospects. The news has drawn attention from biotech investors watching how the FDA's response could affect the company's clinical development plans and share value.
- 2Bank of America Builds $9.88 Million Stake in Disc Medicine▼Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON
Bank of America Corp DE has disclosed a new position worth $9.88 million in Disc Medicine, Inc., the biotech company traded under the ticker IRON. The filing reveals the bank took a fresh stake in the clinical-stage firm, whose stock is often followed by institutional investors in the biotechnology sector.